James Geraghty
Chairman at PIERIS PHARMACEUTICALS, INC.
Net worth: 1 M $ as of 2024-04-29
James Geraghty active positions
Companies | Position | Start | End |
---|---|---|---|
VOYAGER THERAPEUTICS, INC. | Director/Board Member | 2013-12-31 | - |
Independent Dir/Board Member | 2014-09-23 | - | |
Corporate Officer/Principal | 2013-12-31 | 2014-09-23 | |
FULCRUM THERAPEUTICS, INC. | Director/Board Member | 2016-07-18 | - |
Independent Dir/Board Member | 2016-07-18 | - | |
PIERIS PHARMACEUTICALS, INC. | Independent Dir/Board Member | 2017-05-21 | - |
Chairman | 2017-11-20 | - | |
Director/Board Member | 2017-05-21 | 2017-11-20 | |
JUNIPER PHARMACEUTICALS INC | Chairman | - | - |
CANBRIDGE PHARMACEUTICALS INC. | Director/Board Member | 2018-07-17 | - |
Independent Dir/Board Member | 2018-07-17 | - | |
CANbridge Life Sciences Ltd.
CANbridge Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology CANbridge Life Sciences Ltd. produces biopharmaceutical products. It engages in the research and development of therapeutic drug treatment for critical medical condition. The company was founded by James Xue on June 12, 2012 and is headquartered in Chaoyang, China. | Director/Board Member | 2017-04-30 | - |
Independent Dir/Board Member | 2017-04-30 | - | |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Chairman | 2018-06-28 | - |
Bio Ventures for Global Health | Director/Board Member | 2010-10-11 | - |
Therapeutic Human Polyclonals, Inc.
Therapeutic Human Polyclonals, Inc. Pharmaceuticals: MajorHealth Technology Therapeutic Human Polyclonals, Inc. develops human antibody therapeutics. Its technology will enable the generation of monoclonal and polyclonal antibody therapeutics. The company is headquartered in Mountain View, CA. | Director/Board Member | - | - |
░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
Career history of James Geraghty
Former positions of James Geraghty
Companies | Position | Start | End |
---|---|---|---|
░░░░░░░ ░░░░░░░░░░░░ ░░░ | ░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░ ░░░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░ ░░░░ ░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░░ ░░ | ░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░ ░░░░░░░░░ ░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - | - |
░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░░░ | - | - | |
░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░ ░░░░░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░░ | ░░░░░░░░░░ | - | |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - | |
░░░░░░░░ ░░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░ ░░░░░░░░░ | - | - |
░░░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
Training of James Geraghty
Georgetown University | Undergraduate Degree |
Yale Law School | Graduate Degree |
University of Pennsylvania | Graduate Degree |
Statistics
International
United States | 19 |
United Kingdom | 4 |
France | 2 |
Operational
Director/Board Member | 13 |
Chairman | 9 |
Independent Dir/Board Member | 8 |
Sectoral
Health Technology | 19 |
Consumer Services | 4 |
Health Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 6 |
---|---|
BLUEBIRD BIO, INC. | Health Technology |
VOYAGER THERAPEUTICS, INC. | Health Technology |
FULCRUM THERAPEUTICS, INC. | Health Technology |
PIERIS PHARMACEUTICALS, INC. | Health Technology |
CANBRIDGE PHARMACEUTICALS INC. | Health Technology |
ACERAGEN, INC. | Health Technology |
Private companies | 16 |
---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Sanofi SA | Health Technology |
Therapeutic Human Polyclonals, Inc.
Therapeutic Human Polyclonals, Inc. Pharmaceuticals: MajorHealth Technology Therapeutic Human Polyclonals, Inc. develops human antibody therapeutics. Its technology will enable the generation of monoclonal and polyclonal antibody therapeutics. The company is headquartered in Mountain View, CA. | Health Technology |
Genzyme Europe BV
Genzyme Europe BV Pharmaceuticals: MajorHealth Technology Part of Sanofi, Genzyme Europe BV is a Dutch company that develops and manufactures pharmaceutical and biotherapeutic products. The company is based in Amsterdam, Netherlands. | Health Technology |
Caremark International, Inc. | Health Services |
Bio Ventures for Global Health | |
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Health Technology |
Joslin Diabetes Center, Inc.
Joslin Diabetes Center, Inc. Pharmaceuticals: MajorHealth Technology Joslin Diabetes Center, Inc. is a non-profit organization, which engages in the development of pharmaceuticals for diabetes. It provides adult care, pediatric care, eye care, and education programs and classes. The company was founded by Elliott P. Joslin in 1893 and is headquartered in Boston, MA. | Health Technology |
ImmuneXcite, Inc.
ImmuneXcite, Inc. Pharmaceuticals: MajorHealth Technology ImmuneXcite, Inc. operates as a biopharmaceutical company which develops monoclonal antibodies for cancer. The firm provides nivel immuno-incology technology platform, which leverages both the innate and adaptive immune responses to selectively treat a wide range of tumor types. The company was Ifat Rubin-Bejerano, Gerald R. Fink and Yaniv Bejerano and is headquartered in Waltham, MA. | Health Technology |
Catalent JNP, Inc.
Catalent JNP, Inc. Pharmaceuticals: MajorHealth Technology Catalent JNP, Inc. engages in the research and development of drugs and therapeutics. It offers analytical characterization and pre-formulation testing; formulation development; and clinical manufacturing of capsules and tablets. The company was founded in December 1986 and is headquartered in Somerset, NJ. | Health Technology |
Third Rock Ventures LLC
Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Finance |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Health Technology |
Orchard Therapeutics Plc
Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
rEVO Biologics, Inc.
rEVO Biologics, Inc. BiotechnologyHealth Technology rEVO Biologics, Inc. engages in the development and commercialization of specialty therapeutics to address unmet medical needs in patients with rare, life-threatening conditions. Its products include ATryn, which prevents blood clots during and after surgery and childbirth for patients with hereditary antithrombin deficiency. The company was founded in February 1993 and is headquartered in Framingham, MA. | Health Technology |
CANbridge Life Sciences Ltd.
CANbridge Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology CANbridge Life Sciences Ltd. produces biopharmaceutical products. It engages in the research and development of therapeutic drug treatment for critical medical condition. The company was founded by James Xue on June 12, 2012 and is headquartered in Chaoyang, China. | Health Technology |
OMass Therapeutics Ltd.
OMass Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services OMass Therapeutics Ltd. develops native mass spectrometry platform The company was founded by Dame Carol Robinson and is headquartered in Oxford, the United Kingdom. | Commercial Services |
- Stock Market
- Insiders
- James Geraghty
- Experience